Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

被引:55
|
作者
Clark, LH [1 ]
Setzer, RW [1 ]
Barton, HA [1 ]
机构
[1] US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Expt Toxicol Div, Res Triangle Pk, NC 27711 USA
关键词
model evaluation; PBPK models; pharmacokinetics; risk assessment;
D O I
10.1111/j.0272-4332.2004.00561.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Proposed applications of increasingly sophisticated biologically-based computational models, such as physiologically-based pharmacokinetic models, raise the issue of how to evaluate whether the models are adequate for proposed uses, including safety or risk assessment. A six-step process for model evaluation is described. It relies on multidisciplinary expertise to address the biological, toxicological, mathematical, statistical, and risk assessment aspects of the modeling and its application. The first step is to have a clear definition of the purpose(s) of the model in the particular assessment; this provides critical perspectives on all subsequent steps. The second step is to evaluate the biological characterization described by the model structure based on the intended uses of the model and available information on the compound being modeled or related compounds. The next two steps review the mathematical equations used to describe the biology and their implementation in an appropriate computer program. At this point, the values selected for the model parameters (i.e., model calibration) must be evaluated. Thus, the fifth step is a combination of evaluating the model parameterization and calibration against data and evaluating the uncertainty in the model outputs. The final step is to evaluate specialized analyses that were done using the model, such as modeling of population distributions of parameters leading to population estimates for model outcomes or inclusion of early pharmacodynamic events. The process also helps to define the kinds of documentation that would be needed for a model to facilitate its evaluation and implementation.
引用
收藏
页码:1697 / 1717
页数:21
相关论文
共 50 条
  • [41] PHYSIOLOGICALLY-BASED PHARMACOKINETICS CANCER RISK ASSESSMENT
    ANDERSEN, ME
    KRISHNAN, K
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 : 103 - 108
  • [42] Physiologically-based pharmacokinetic analysis of grepafloxacin
    Nakajima, Y
    Hattori, K
    Shinsei, M
    Matsunaga, N
    Iizasa, H
    Sasabe, H
    Akiyama, H
    Miyamoto, G
    Nakashima, E
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (09) : 1077 - 1083
  • [43] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY
    Liu, X.
    Leong, R.
    Buckart, G.
    Dallmann, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S117 - S117
  • [44] Physiologically-based pharmacokinetic simulation modelling
    Grass, GM
    Sinko, PJ
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (03) : 433 - 451
  • [45] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR ACETONE
    KUMAGAI, S
    MATSUNAGA, I
    OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1995, 52 (05) : 344 - 352
  • [46] Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models
    Sabine Pilari
    Wilhelm Huisinga
    Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37 : 365 - 405
  • [47] Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models
    Pilari, Sabine
    Huisinga, Wilhelm
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (04) : 365 - 405
  • [48] A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
    Sjogren, Erik
    Tarning, Joel
    Barnes, Karen, I
    Jonsson, E. Niclas
    PHARMACEUTICS, 2021, 13 (02) : 1 - 23
  • [49] INCORPORATION OF TEMPORAL FACTORS INTO PHYSIOLOGICALLY-BASED KINETIC-MODELS FOR RISK ASSESSMENT
    OFLAHERTY, EJ
    POLAK, J
    ANDRIOT, MD
    INHALATION TOXICOLOGY, 1995, 7 (06) : 917 - 925
  • [50] PREDICTION OF ANTICHOLINESTERASE ACTIVITY AND URINARY METABOLITES OF ISOFENPHOS - USE OF A PERCUTANEOUS PHYSIOLOGICALLY-BASED PHARMACOKINETIC PHYSIOLOGICALLY-BASED PHARMACODYNAMIC MODEL
    KNAAK, JB
    ALBAYATI, MA
    RAABE, OG
    BLANCATO, JN
    BIOMARKERS OF HUMAN EXPOSURE TO PESTICIDES, 1994, 542 : 284 - 300